Zai Lab And Innoviva Specialty Therapeutics Receives NMPA Approval For XACDURO (Sulbactam-Durlobactam) For Hospital-Acquired And Ventilator-Associated Pneumonia Caused By Acinetobacter Baumannii-Calcoaceticus Complex In China

5/20/24 12:40:14 AM ET

$INVA

$ZLAB

Biotechnology: Pharmaceutical Preparations

Health Care

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $INVA alert in real time by email

Drug-resistant Acinetobacter baumannii is a growing global health threat and high priority pathogen needing new antibiotics, according to World Health Organization
China NMPA approval based on comprehensive clinical data demonstrating robust activity of SUL-DUR against carbapenem-resistant bacterial strains
In China, it is estimated there are approximately 300,000 cases of Acinetobacter infections and approximately 74% of them are carbapenem-resistant

Get the next $INVA alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$INVA
$ZLAB

Company	Date	Price Target	Rating	Analyst
Innoviva Inc. $INVA	2/17/2026	$35.00	Buy	BTIG Research
Innoviva Inc. $INVA	9/30/2025	$17.00	Sell	Goldman
Zai Lab Limited $ZLAB	8/25/2025	$52.00	Buy	Jefferies
Innoviva Inc. $INVA	8/11/2025	$45.00	Outperform	Oppenheimer
Innoviva Inc. $INVA	7/14/2025	$40.00	Buy	H.C. Wainwright
Innoviva Inc. $INVA	7/11/2025	$26.00	Overweight	Cantor Fitzgerald
Innoviva Inc. $INVA	3/7/2025	$55.00	Sector Outperform	Scotiabank
Zai Lab Limited $ZLAB	3/7/2025	$55.00	Sector Outperform	Scotiabank

More analyst ratings

$INVA
$ZLAB
Press Releases

Fastest customizable press release news feed in the world

View All

Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026

- Company to host conference call and webcast on May 7, 2026, at 8:00 a.m. ET (8:00 p.m. HKT) Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) today announced that it will report its first quarter 2026 financial results and provide recent corporate updates on May 7, 2026, before the opening of U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT). Conference Call and Webcast Information The live webcast can be accessed by visiting the Company's website at http://ir.zailaboratory.com. Participants must register in advance of the conference call. Details are as follows: Registration link for webcast (preferred): https://ed

4/22/26 7:30:00 AM ET

$ZLAB

Biotechnology: Pharmaceutical Preparations

Health Care

Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas

Zoci, a potential first-in-class DLL3-targeting antibody drug conjugate, showed a 53.7% confirmed intracranial objective response rate (iORR) for small cell lung cancer (SCLC) with brain metastases; at 1.6 mg/kg dose, the confirmed iORR was 62.5% (10/16), including complete responses Encouraging activity was observed in extrapulmonary neuroendocrine carcinomas (NECs), with a 38.2% confirmed objective response rate Global Phase 3 trial ongoing in second-line-plus SCLC; first-line SCLC and neuroendocrine carcinoma programs advancing toward registrational phase in 2026 Investor conference call and webcast to discuss data being presented at AACR Annual Meeting 2026 and clinical trial

4/17/26 3:01:00 PM ET

$ZLAB

Biotechnology: Pharmaceutical Preparations

Health Care

Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs). Phase Ib/II study will test the combination of obrixtamig, a DLL3/CD3 T‑cell engager, with Zai Lab's zocilurtatug pelitecan (zoci), a DLL3‑targeting antibody–drug conjugate (ADC), to explore safety and potential increase in clinical benefit for patients. Ingelheim, Germany and Shanghai, China/Cambridge, Mass. – 15 April, 2026 – Boehringer Ingelheim and Zai Lab (NASDAQ:ZLAB, HKEX: 9688)) today announced a clinical collaboration focused on pioneering a dual DLL3-targeting combination. The Phase Ib/

4/15/26 8:00:00 AM ET

$ZLAB

Biotechnology: Pharmaceutical Preparations

Health Care

$INVA
$ZLAB
Financials

Live finance-specific insights

View All

Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026

4/22/26 7:30:00 AM ET

$ZLAB

Biotechnology: Pharmaceutical Preparations

Health Care

Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas

4/17/26 3:01:00 PM ET

$ZLAB

Biotechnology: Pharmaceutical Preparations

Health Care

Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

– Total revenues grew 17% y-o-y to $127.6 million for the fourth quarter of 2025 and 15% y-o-y to $460.2 million for the full-year 2025 – Zocilurtatug pelitecan (zoci) on track to become Zai Lab's first global oncology launch, with three registration-enabling studies across 2L+ SCLC, 1L SCLC, and extrapulmonary NECs by the end of 2026 – Advancing a differentiated global pipeline, including ZL-1503 (IL-13/IL-31Rα), ZL-6201 (LRRC15 ADC), ZL-1222 (PD-1/IL-12) and ZL-1311 (MUC17/CD3 TCE) – Key regional programs continue to advance, with KarXT approved in China and commercial launch preparations underway; pivotal data readouts for povetacicept in IgAN and elegrobart in TED expected in 2026

2/26/26 7:00:00 AM ET

$ZLAB

Biotechnology: Pharmaceutical Preparations

Health Care

$INVA
$ZLAB
Leadership Updates

Live Leadership Updates

View All

The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man

10/21/25 8:05:00 AM ET

$CRVS

$DNA

$EXEL

Biotechnology: Pharmaceutical Preparations

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D

Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) announced today that following a distinguished career, Harald Reinhart, M.D., President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases (NSAiID) of Zai Lab, will retire at the end of June, after which he will serve as a senior advisor for the Company. Rafael Amado, M.D., President, Head of Global Oncology Research and Development of Zai Lab, will expand his role and assume responsibility for all of the Company's Global R&D upon Dr. Reinhart's retirement. "Harald has devoted nearly 50 years to treating patients, first as a physician and later discovering and developing innovative therapies to bring to patients in

6/11/24 4:05:00 PM ET

$ZLAB

Biotechnology: Pharmaceutical Preparations

Health Care

Innoviva Appoints Stephen Basso as Chief Financial Officer

Innoviva, Inc. (NASDAQ:INVA) ("Innoviva" and "the Company"), a diversified holding company with a portfolio of royalties and other healthcare assets, today announced the appointment of Stephen Basso as its Chief Financial Officer, effective August 21, 2023. "We are excited to welcome Stephen to our executive leadership team and believe the Company will benefit greatly from his background and experience," said Pavel Raifeld, Chief Executive Officer of Innoviva. "I look forward to working with Stephen to advance our strategy and create shareholder value." Mr. Basso brings more than 30 years of experience in the financial services industry and financial leadership in the pharmaceutical ind

8/25/23 4:52:00 PM ET

$INVA

Biotechnology: Pharmaceutical Preparations

Health Care

Zai Lab And Innoviva Specialty Therapeutics Receives NMPA Approval For XACDURO (Sulbactam-Durlobactam) For Hospital-Acquired And Ventilator-Associated Pneumonia Caused By Acinetobacter Baumannii-Calcoaceticus Complex In China

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$INVA
$ZLAB

Zai Lab And Innoviva Specialty Therapeutics Receives NMPA Approval For XACDURO (Sulbactam-Durlobactam) For Hospital-Acquired And Ventilator-Associated Pneumonia Caused By Acinetobacter Baumannii-Calcoaceticus Complex In China

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$INVA
$ZLAB

$INVA
$ZLAB
Press Releases

Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026

Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas

Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

$INVA
$ZLAB
Analyst Ratings

BTIG Research initiated coverage on Innoviva with a new price target

Goldman initiated coverage on Innoviva with a new price target

Jefferies resumed coverage on Zai Lab with a new price target

$INVA
$ZLAB
SEC Filings

SEC Form PRE 14A filed by Zai Lab Limited

SEC Form SCHEDULE 13G filed by Zai Lab Limited

SEC Form 144 filed by Zai Lab Limited

$INVA
$ZLAB
Insider Trading

SEC Form 4 filed by Smiley Joshua L

SEC Form 4 filed by Edmondson Frazor Titus Iii

SEC Form 4 filed by Du Ying

$INVA
$ZLAB
Financials

Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026

Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas

Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

$INVA
$ZLAB
Insider Purchases

Officer Smiley Joshua L bought $289,100 worth of American Depositary Shares (10,000 units at $28.91), increasing direct ownership by 13% to 86,604 units (SEC Form 4)

Smiley Joshua L bought $64,200 worth of American Depositary Shares (3,000 units at $21.40), increasing direct ownership by 10% to 31,684 units (SEC Form 4)

Smiley Joshua L bought $62,490 worth of American Depositary Shares (3,000 units at $20.83), increasing direct ownership by 15% to 23,527 units (SEC Form 4)

$INVA
$ZLAB
Leadership Updates

The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D

Innoviva Appoints Stephen Basso as Chief Financial Officer

$INVA
$ZLAB
Large Ownership Changes

Amendment: SEC Form SC 13D/A filed by Innoviva Inc.

SEC Form SC 13G filed by Zai Lab Limited

Amendment: SEC Form SC 13G/A filed by Zai Lab Limited

Zai Lab And Innoviva Specialty Therapeutics Receives NMPA Approval For XACDURO (Sulbactam-Durlobactam) For Hospital-Acquired And Ventilator-Associated Pneumonia Caused By Acinetobacter Baumannii-Calcoaceticus Complex In China

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $INVA$ZLAB

Zai Lab And Innoviva Specialty Therapeutics Receives NMPA Approval For XACDURO (Sulbactam-Durlobactam) For Hospital-Acquired And Ventilator-Associated Pneumonia Caused By Acinetobacter Baumannii-Calcoaceticus Complex In China

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $INVA$ZLAB

$INVA$ZLAB Press Releases

Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026

Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas

Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas

$INVA$ZLAB Analyst Ratings

BTIG Research initiated coverage on Innoviva with a new price target

Goldman initiated coverage on Innoviva with a new price target

Jefferies resumed coverage on Zai Lab with a new price target

$INVA$ZLAB SEC Filings

SEC Form PRE 14A filed by Zai Lab Limited

SEC Form SCHEDULE 13G filed by Zai Lab Limited

SEC Form 144 filed by Zai Lab Limited

$INVA$ZLAB Insider Trading

SEC Form 4 filed by Smiley Joshua L

SEC Form 4 filed by Edmondson Frazor Titus Iii

SEC Form 4 filed by Du Ying

$INVA$ZLAB Financials

Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026

Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas

Zai Lab Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates

$INVA$ZLAB Insider Purchases

Officer Smiley Joshua L bought $289,100 worth of American Depositary Shares (10,000 units at $28.91), increasing direct ownership by 13% to 86,604 units (SEC Form 4)

Smiley Joshua L bought $64,200 worth of American Depositary Shares (3,000 units at $21.40), increasing direct ownership by 10% to 31,684 units (SEC Form 4)

Smiley Joshua L bought $62,490 worth of American Depositary Shares (3,000 units at $20.83), increasing direct ownership by 15% to 23,527 units (SEC Form 4)

$INVA$ZLAB Leadership Updates

The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D

Innoviva Appoints Stephen Basso as Chief Financial Officer

$INVA$ZLAB Large Ownership Changes

Amendment: SEC Form SC 13D/A filed by Innoviva Inc.

SEC Form SC 13G filed by Zai Lab Limited

Amendment: SEC Form SC 13G/A filed by Zai Lab Limited

Recent Analyst Ratings for
$INVA
$ZLAB

Recent Analyst Ratings for
$INVA
$ZLAB

$INVA
$ZLAB
Press Releases

$INVA
$ZLAB
Analyst Ratings

$INVA
$ZLAB
SEC Filings

$INVA
$ZLAB
Insider Trading

$INVA
$ZLAB
Financials

$INVA
$ZLAB
Insider Purchases

$INVA
$ZLAB
Leadership Updates

$INVA
$ZLAB
Large Ownership Changes